文献速递白血病造血干细胞移植与细胞治疗

氟达拉滨-曲奥舒凡与氟达拉滨-美法仑预处理方案在成人急性淋巴细胞白血病中的比较

Fludarabine-treosulfan compared with fludarabine-melphalan conditioning for adult acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2026-10-28

该回顾性注册研究纳入967例接受首次异基因造血干细胞移植的成人急性淋巴细胞白血病患者,比较氟达拉滨-曲奥舒凡(Flu/Treo)与氟达拉滨-美法仑(Flu/Mel)预处理方案。2年总生存率分别为65.6%和60.5%,无白血病生存率分别为57.2%和49.7%。多因素分析显示Flu/Treo与复发率降低相关(HR 0.61,p=0.011),但总生存和无白血病生存无显著差异,非复发死亡率相似。

要点

  • Flu/Treo较Flu/Mel显著降低复发率(HR 0.61,p=0.011),尤其B-ALL患者。
  • 两组2年非复发死亡率相似(18.6% vs 18.8%)。
  • 总生存和无白血病生存无显著差异,支持Flu/Treo作为合理替代。

核心结论

  • 在成人ALL中,Flu/Treo较Flu/Mel降低复发率且不增加非复发死亡率,但未显著改善总生存或无白血病生存。

研究设计与样本

  • 回顾性注册研究,纳入2012–2024年967例首次allo-HSCT的成人B-或T-ALL患者(CR1或CR2+),Flu/Mel组778例,Flu/Treo组189例。

主要发现

  • 2年总生存率Flu/Treo组65.6% vs Flu/Mel组60.5%,无白血病生存率57.2% vs 49.7%。
  • 2年复发率Flu/Treo组24.1% vs Flu/Mel组31.5%,非复发死亡率18.6% vs 18.8%。
  • 多因素分析中预处理方案对总生存和无白血病生存无显著影响,但Flu/Treo与复发率降低相关(HR 0.61,p=0.011)。
  • B-ALL亚组结果相似,T-ALL亚组无差异。

关键数值与推荐

  • 2年总生存率65.6% vs 60.5%,无白血病生存率57.2% vs 49.7%,复发率24.1% vs 31.5%,非复发死亡率18.6% vs 18.8%。
  • 复发率风险比HR 0.61(p=0.011), favoring Flu/Treo。

临床怎么用

  • 对于成人ALL患者,Flu/Treo可作为合理的替代预处理平台,尤其B-ALL患者可能获益于复发率降低。

局限性

  • 回顾性注册研究设计,Flu/Treo组移植时间更近、单倍体供者更多、超越CR1者更多,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal conditioning strategy for adult acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains undefined, particularly in older or medically vulnerable patients. Reduced-intensity regimens lower non-relapse mortality (NRM) but increase relapse risk. Treosulfan-based conditioning may represent an intermediate-intensity alternative, though comparative data in ALL are limited. We conducted a retrospective registry-based study including 967 adult patients with B- or T-ALL undergoing first allo-HSCT in complete remission (CR1 or CR2+) between 2012 and 2024. Patients received fludarabine-melphalan (Flu/Mel, n=778) or fludarabine-treosulfan (Flu/Treo, n=189). The primary endpoint was leukemia-free survival (LFS); secondary endpoints included overall survival (OS), relapse incidence (RI), NRM, and graft-versus-host disease. Outcomes were censored at 2 years. Multivariable Cox models adjusted for clinical and transplant-related variables. Flu/Treo recipients were transplanted more recently, more often received haploidentical donors, and were more frequently beyond CR1. Median age was slightly higher in the Flu/Treo group. At 2 years, OS was 65.6% with Flu/Treo versus 60.5% with Flu/Mel, and LFS 57.2% versus 49.7%. RI was lower with Flu/Treo (24.1% vs 31.5%), while NRM was similar (18.6% vs 18.8%). In multivariable analysis, conditioning regimen did not significantly affect OS or LFS, but Flu/Treo was associated with reduced RI (HR 0.61, p=0.011) without differences in NRM. Similar results were observed in B-ALL, while no differences emerged in T-ALL. Flu/Treo was associated with a lower relapse incidence compared with Flu/Mel, particularly in patients with B-cell ALL, without an increase in non-relapse mortality. However, no significant differences were observed in overall survival or leukemia-free survival. These findings support Flu/Treo as a reasonable alternative conditioning platform for adult patients with ALL and warrant prospective validation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Avenoso, Farina, Malagola, et al. Fludarabine-treosulfan compared with fludarabine-melphalan conditioning for adult acute lymphoblastic leukemia. Blood Adv. 2026. PMID: 42954476. doi:10.1182/bloodadvances.2026021035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。